82 FR 4366 - Government-Owned Inventions; Availability for Licensing

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

Federal Register Volume 82, Issue 9 (January 13, 2017)

The invention listed below is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.

[Federal Register Volume 82, Number 9 (Friday, January 13, 2017)]
[Notices]
[Page 4366]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2017-00735]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The invention listed below is owned by an agency of the U.S. 
Government and is available for licensing to achieve expeditious 
commercialization of results of federally-funded research and 
development. Foreign patent applications are filed on selected 
inventions to extend market coverage for companies and may also be 
available for licensing.

FOR FURTHER INFORMATION CONTACT: Licensing information and copies of 
the patent applications listed below may be obtained by communicating 
with the indicated licensing contact at the Technology Transfer and 
Intellectual Property Office, National Institute of Allergy and 
Infectious Diseases, 5601 Fishers Lane, Rockville, MD 20852; tel. 301-
496-2644. A signed Confidential Disclosure Agreement will be required 
to receive copies of unpublished patent applications.

SUPPLEMENTARY INFORMATION: Technology description follows.

Monoclonal Antibodies That Neutralize Norovirus

    Description of Technology: Vaccines and therapies to prevent and 
treat Norovirus infections do not exist, despite the worldwide 
prevalence of Norovirus infections. Outbreaks of human gastroenteritis 
attributable to Norovirus commonly occur in group setting, such as 
hospitals, nursing homes, schools, dormitories, cruise ships and 
military barracks. This technology relates to chimpanzee-human chimeric 
monoclonal antibodies, which specifically bind to Norovirus and have 
therapeutic potential. The antibodies that were tested in a primate 
model of infection have shown protection against Norovirus. These 
Norovirus antibodies may have application as immunoprophylaxis to 
protect individuals from infections or as a possible treatment for 
infected individuals, or can be used to develop a diagnostic for 
detection of norovirus infections.
    This technology is available for licensing for commercial 
development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as 
well as for further development and evaluation under a research 
collaboration.
    Potential Commercial Applications:

 Therapeutics
 Diagnostics

    Competitive Advantages:

 There are currently no vaccines or therapeutics available 
against Norovirus infections

    Development Stage:

 In vivo data available (animal)

    Inventors: Zhaochun Chen, Robert H. Purcell, Lisbeth Kim Green, 
Stanislav Sosnovtsev, Karin Bok (all from NIAID).
    Publications: Chen Z, et al., Development of Norwalk virus-specific 
monoclonal antibodies with therapeutic potential for the treatment of 
Norwalk virus gastroenteritis, J Virol. 2013 Sep; 87(17):9547-57. [PMID 
23785216].
    Intellectual Property: HHS Reference No. E-226-2011/0--U.S. 
Provisional Application No. 61/763,879, filed February 12, 2013; PCT 
Application No. PCT/US2014/015809, filed February 11, 2014; European 
Application No. 14706239.2, filed August 5, 2015 (pending); U.S. 
Application No. 14/767,274, filed August 11, 2015 (allowed); and U.S. 
Application No. 15/359,438, filed November 22, 2016 (pending).
    Licensing Contact: Dr. Jenish Patel, 240-669-2894; 
[email protected].
    Collaborative Research Opportunity: The National Institute of 
Allergy and Infectious Diseases is seeking statements of capability or 
interest from parties interested in collaborative research to further 
develop, evaluate or commercialize for development of a therapeutic or 
a diagnostic for Norovirus infections. For collaboration opportunities, 
please contact Dr. Jenish Patel, 240-669-2894; [email protected].

    Dated: January 9, 2017.
Suzanne Frisbie,
Deputy Director, Technology Transfer and Intellectual Property Office, 
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2017-00735 Filed 1-12-17; 8:45 am]
 BILLING CODE 4140-01-P